IP Library Granted Patent US 11,779,586
Granted Patent B2
US 11,779,586 · App. 17/071,543 · Granted Oct 10, 2023

Compounds comprising tricyclic heterocyclic compounds

Inventors: Stephen Joseph Shuttleworth (Oxfordshire, GB); Elisabeth Ann Bone (Oxfordshire, GB); Franck Alexandre Silva (Oxfordshire, GB); Alexander Richard Liam Cecil (Oxfordshire, GB)
Assignee: Convalife (Shanghai) Co. Limited
A61K31/5377A61K9/2018A61K9/2027A61K9/2054A61K9/2095A61K31/5386
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,586
App. No.
17/071,543
Granted
Oct 10, 2023
Kind
B2
Abstract

The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:

Claims (18)

1. A pharmaceutical composition comprising a succinate salt of a compound, wherein the compound is represented by:

and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants.

2. The composition according to claim 1 , further comprising a surfactant in an amount of from 0.1 to 5 wt % based on the total weight of the composition.

3. The composition according to claim 1 , wherein the composition is in the form of a tablet or capsule.

4. The composition according to claim 1 , wherein the composition comprises at least two pharmaceutical excipients.

5. The composition according to claim 1 , wherein the compound is present in an amount of from 5 to 30 wt % based on the total weight of the composition.

6. The composition according to claim 1 , wherein a filler is present in an amount of from 10 to 90 wt % based on the total weight of the composition.

7. The composition according to claim 1 , wherein a binder is present in an amount of from 0.1 to 20 wt % based on the total weight of the composition.

8. The composition according to claim 1 , wherein a disintegrant is present in an amount of from 1 to 20 wt % based on the total weight of the composition.

9. The composition according to claim 1 , wherein a lubricant is present in an amount of from 0.1 to 10 wt % based on the total weight of the composition.

10. The composition according to claim 1 , wherein the composition comprises:

1 to 50 wt % of a compound according to claim 1 ;

10 to 90 wt % of at least one filler;

0.1 to 20 wt % of at least one binder;

1 to 20 wt % of at least one disintegrant; and

0.1 to 10 wt % of at least one lubricant or glidant.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical excipient is selected from the group consisting of lactose monohydrate, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, magnesium stearate, and sodium lauryl sulfate.

12. The pharmaceutical composition of claim 1 , wherein the composition comprises sodium lauryl sulfate, lactose monohydrate, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, and magnesium stearate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: KARUS THERAPEUTICS LIMITED
To: CONVALIFE (SHANGHAI) CO. LIMITED
Reel/Frame 061315/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2021
From: SHUTTLEWORTH, STEPHEN JOSEPH; BONE, ELISABETH ANN; SILVA, FRANCK ALEXANDRE; CECIL, ALEXANDER RICHARD LIAM
To: KARUS THERAPEUTICS LIMITED
Reel/Frame 055078/0679 →
Priority Claims (1)
GB 1514758 · Aug 19, 2015 · national
Continuity (2)
Continuation 15753359
Related Publication 20210275537A1 · Sep 9, 2021
Cited By (2)
US 12,257,254 US 12,551,487